Current immunotherapeutic approaches in t cell non-hodgkin lymphomas

Teresa Poggio, Justus Duyster, Anna L. Illert

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. With the exception of a few relatively indolent entities, T-NHL is typically aggressive, treatment resistant, and associated with poor prognosis. Relatively few options with proven clinical benefit are available for patients with relapsed or refractory disease. Immunotherapy has emerged as a promising treatment for the management of patients with hematological malignancies. The identification of tumor antigens has provided a large number of potential targets. Therefore, several monoclonal antibodies (alemtuzumab, SGN-30, brentuximab vedotin, and mogamulizumab), directed against tumor antigens, have been investigated in different subtypes of T-NHL. In addition to targeting antigens involved in cancer cell physiology, antibodies can stimulate immune effector functions or counteract immunosuppressive mechanisms. Chimeric antigen receptor (CAR)-T cells directed against CD30 and immune checkpoint inhibitors are currently being investigated in clinical trials. In this review, we summarize the currently available clinical evidence for immunotherapy in T-NHL, focusing on the results of clinical trials using first generation monoclonal antibodies, new immunotherapeutic agents, immune checkpoint inhibitors, and CAR-T cell therapies.

Original languageEnglish
Article number339
Issue number9
StatePublished - 18 Sep 2018
Externally publishedYes


  • Brentuximab vedotin
  • Checkpoint inhibitors
  • Chimeric antigen receptor (car)-t cell
  • Monoclonal antibodies
  • T cell non-hodgkin lymphoma (t-nhl)


Dive into the research topics of 'Current immunotherapeutic approaches in t cell non-hodgkin lymphomas'. Together they form a unique fingerprint.

Cite this